Alcoholic liver disease secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Alcoholic liver disease}} | {{Alcoholic liver disease}} | ||
{{CMG}}; {{AE}} {{MKA}} | |||
==Overview== | ==Overview== | ||
Effective measures for the [[secondary prevention]] of alcoholic liver disease include abstinence. Abstinence can be achieved through drug therapies in an inpatient as well as an out patient setting. | |||
==Secondary Prevention== | |||
*Effective measures for the [[secondary prevention]] of alcoholic liver disease include:<ref name="pmid19489992">{{cite journal |vauthors=Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N |title=The effectiveness of brief alcohol interventions in primary care settings: a systematic review |journal=Drug Alcohol Rev |volume=28 |issue=3 |pages=301–23 |year=2009 |pmid=19489992 |doi=10.1111/j.1465-3362.2009.00071.x |url=}}</ref><ref name="pmid8925349">{{cite journal |vauthors=Moos RH, King MJ, Patterson MA |title=Outcomes of residential treatment of substance abuse in hospital- and community-based programs |journal=Psychiatr Serv |volume=47 |issue=1 |pages=68–74 |year=1996 |pmid=8925349 |doi=10.1176/ps.47.1.68 |url=}}</ref><ref name="pmid15200577">{{cite journal |vauthors=Bouza C, Angeles M, Magro A, Muñoz A, Amate JM |title=Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review |journal=Addiction |volume=99 |issue=7 |pages=811–28 |year=2004 |pmid=15200577 |doi=10.1111/j.1360-0443.2004.00763.x |url=}}</ref><ref name="pmid10208148">{{cite journal |vauthors=Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT |title=Pharmacological treatment of alcohol dependence: a review of the evidence |journal=JAMA |volume=281 |issue=14 |pages=1318–25 |year=1999 |pmid=10208148 |doi= |url=}}</ref><ref name="pmid19630744">{{cite journal |vauthors=Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM |title=Review of topiramate: an antiepileptic for the treatment of alcohol dependence |journal=Curr Drug Abuse Rev |volume=2 |issue=2 |pages=135–42 |year=2009 |pmid=19630744 |doi= |url=}}</ref><ref name="pmid18068515">{{cite journal |vauthors=Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G |title=Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study |journal=Lancet |volume=370 |issue=9603 |pages=1915–22 |year=2007 |pmid=18068515 |doi=10.1016/S0140-6736(07)61814-5 |url=}}</ref><ref name="pmid7672043">{{cite journal |vauthors=Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F |title=The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease |journal=Eur. J. Epidemiol. |volume=10 |issue=6 |pages=657–64 |year=1994 |pmid=7672043 |doi= |url=}}</ref><ref name="pmid1476147">{{cite journal |vauthors=Klatsky AL, Armstrong MA |title=Alcohol, smoking, coffee, and cirrhosis |journal=Am. J. Epidemiol. |volume=136 |issue=10 |pages=1248–57 |year=1992 |pmid=1476147 |doi= |url=}}</ref><ref name="pmid8985274">{{cite journal |vauthors=Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC |title=Excess weight risk factor for alcoholic liver disease |journal=Hepatology |volume=25 |issue=1 |pages=108–11 |year=1997 |pmid=8985274 |doi=10.1002/hep.510250120 |url=}}</ref> | |||
**[[Naltrexone]] or [[acamprosate]] to prevent relapse | |||
**[[Disulfiram]] and [[topiramate]] for decreasing craving and [[withdrawal symptoms]] | |||
**[[Smoking cessation]] and [[weight loss]] where indicated | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | |||
{{WH}} | {{WH}} | ||
[[Category: | [[Category:Surgery]] | ||
[[Category:Gastroenterology]] | [[Category:Gastroenterology]] | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Hepatology]] | [[Category:Hepatology]] | ||
[[Category:Medicine]] | |||
Latest revision as of 20:20, 29 July 2020
|
Alcoholic liver disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Alcoholic liver disease secondary prevention On the Web |
|
American Roentgen Ray Society Images of Alcoholic liver disease secondary prevention |
|
Risk calculators and risk factors for Alcoholic liver disease secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]
Overview
Effective measures for the secondary prevention of alcoholic liver disease include abstinence. Abstinence can be achieved through drug therapies in an inpatient as well as an out patient setting.
Secondary Prevention
- Effective measures for the secondary prevention of alcoholic liver disease include:[1][2][3][4][5][6][7][8][9]
- Naltrexone or acamprosate to prevent relapse
- Disulfiram and topiramate for decreasing craving and withdrawal symptoms
- Smoking cessation and weight loss where indicated
References
- ↑ Kaner EF, Dickinson HO, Beyer F, Pienaar E, Schlesinger C, Campbell F, Saunders JB, Burnand B, Heather N (2009). "The effectiveness of brief alcohol interventions in primary care settings: a systematic review". Drug Alcohol Rev. 28 (3): 301–23. doi:10.1111/j.1465-3362.2009.00071.x. PMID 19489992.
- ↑ Moos RH, King MJ, Patterson MA (1996). "Outcomes of residential treatment of substance abuse in hospital- and community-based programs". Psychiatr Serv. 47 (1): 68–74. doi:10.1176/ps.47.1.68. PMID 8925349.
- ↑ Bouza C, Angeles M, Magro A, Muñoz A, Amate JM (2004). "Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review". Addiction. 99 (7): 811–28. doi:10.1111/j.1360-0443.2004.00763.x. PMID 15200577.
- ↑ Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT (1999). "Pharmacological treatment of alcohol dependence: a review of the evidence". JAMA. 281 (14): 1318–25. PMID 10208148.
- ↑ Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM (2009). "Review of topiramate: an antiepileptic for the treatment of alcohol dependence". Curr Drug Abuse Rev. 2 (2): 135–42. PMID 19630744.
- ↑ Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D'Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007). "Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study". Lancet. 370 (9603): 1915–22. doi:10.1016/S0140-6736(07)61814-5. PMID 18068515.
- ↑ Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D'Amicis A, Aricó S, di Orio F (1994). "The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease". Eur. J. Epidemiol. 10 (6): 657–64. PMID 7672043.
- ↑ Klatsky AL, Armstrong MA (1992). "Alcohol, smoking, coffee, and cirrhosis". Am. J. Epidemiol. 136 (10): 1248–57. PMID 1476147.
- ↑ Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC (1997). "Excess weight risk factor for alcoholic liver disease". Hepatology. 25 (1): 108–11. doi:10.1002/hep.510250120. PMID 8985274.